Despite definitive conclusions in this regard cannot be drawn, results of some studies seem to indicate that the protective effect of the TNF antagonists in IBD patients can be ascribed to the reduction of the hyper-inflammatory responses frequently found in the most severe COVID-19 cases. This evidence concerns the gene TNF and inflammatory bowel disease.